Medtronic Diabetes warning letter removed by FDA
Wolterk/iStock Editorial via Getty Images
- The US FDA has lifted a warning letter issued in December 2021 against Medtronic's (NYSE:MDT) diabetes unit after the company took remediation action.
- The letter was sent to the unit's Northridge, Calif., headquarters.
- Medtronic (MDT) added that all regulatory restrictions associated have now been resolved.
- Just a few days ago, the FDA approved the company's new MiniMed insulin pump.